Scholar Rock wins FDA approval for ISEMBYLD, a muscle-targeted SMA treatment on September 14, 2026 apitegromab Approved Infrequent ISEMBYLD Motor function (observable entity) Scholar Rock SMN2 gene Spinal Muscular Atrophy United States Food and Drug Administration +